Medical therapy of unstable angina and non-Q-wave myocardial infarction

American Journal of Cardiology

Volumn 86, Issue 8 SUPPL. 2, 2000, Pages 24-33

  Abrams, Jonathan ^a,b  

^a UNIVERSITY OF NEW MEXICO HOSPITAL   (United States)

^b UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIOCHEMICAL MARKER; C REACTIVE PROTEIN; CALCIUM ANTAGONIST; CREATINE KINASE; EPTIFIBATIDE; GLYCERYL TRINITRATE; LOW MOLECULAR WEIGHT HEPARIN; NITRATE; STATIN; TIROFIBAN; TROPONIN;

CLINICAL PRACTICE; DECISION MAKING; DRUG EFFICACY; EXPERIENCE; HEART INFARCTION; HUMAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; Q WAVE; RECEPTOR BLOCKING; REVIEW; UNSTABLE ANGINA PECTORIS;

EID: 0034687332     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(00)01341-2     Document Type: Article

References (58)

1. Elevated levels of C-reactive protein at discharge in patients with unstable angina predict recurrent instability
2. Production of C-reactive protein and risk of coronary events in stable and unstable angina
3. Guidelines for the diagnosis and management of unstable angina and non-Q-wave myocardial infarction: Proposed revisions
4. Should the emergence of new agents change the management of patients with acute coronary syndromes without ST-segment elevation?
5. Unstable angina pectoris
6. Unstable angina and non-Q wave myocardial infraction: Does the clinical diagnosis have therapeutic implications?
7. Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: The CAPTURE study
8. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes
9. Platelet GPIIb-IIIa blockers
10. Emergency room triage of patients with acute chest pain by means of rapid testing for cardiac troponin T or troponin I
11. Cardiac-specific troponin I levels to predict the risk of mortality in patients with acute coronary syndromes
12. Incremental effects of anti-platelet, anti-thrombin and fibrinolytic therapy on the speed and stability of ST-segment recovery after acute MI
13. Long-term low-molecular-mass heparin in unstable coronary-artery disease: FRISC II prospective randomised multicentre study
14. Prognostic value of the admission electrocardiogram in acute coronary syndromes
15. Aspirin, heparin, or both to treat acute unstable angina
16. Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina: Results of a Veterans Administration Cooperative Study
17. Previous aspirin use may attenuate the severity of the manifestations of acute ischaemia syndromes
18. A randomised, blinded trial of clopidogrel versus aspirin in patients at high risk of ischemic events (CAPRIE)
19. Thrombotic thrombocytoenic purpura associated with clopidogrel
20. Collaborative overview of randomised trials of antiplatelet therapy. I. Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients
21. Efficacy of low-molecular-weight heparin in acute coronary syndromes
22. The emerging role of low-molecular-weight heparin in cardiovascular medicine
23. Low molecular weight heparins in the management of unstable angina/non-Q-wave myocardial infarction
24. Low-molecular-weight heparin during instability in coronary artery disease
25. Comparison of low-molecular-weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease: Fragmin in Unstable Coronary Artery Disease Study (FRIC)
26. Comparison of two treatment durations (6 days and 14 days) of a low molecular weight heparin with a 6-day treatment of unfractionated heparin in the initial management of unstable angina or non-Q-wave myocardial infarction: FRAXIS: (Fraxiparine in Ischaemic Syndrome)
27. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease
28. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction: Results of the Thrombolysis in Myocardial Infarction (TIMI) IIB trial
29. Assessment of the treatment effect of enoxaparin for unstable angina/non-Q-wave myocardial infraction-TIMI IIB-essence meta-analysis
30. Nitrates
31. Therapy with nitroglycerin increases coronary vasoconstriction in response to acetylcholine
32. Heparin resistance induced by intravenous nitroglycerin: A word of caution when both drugs are used concomitantly
33. Absence of drug interaction between heparin and nitroglycerin: Randomized placebo-controlled crossover study
34. Lack of in vitro interaction between heparin and nitroglycerin
35. Antiplatelet and antithrombotic effects of organic nitrates
36. Effect of nitroprusside on regional myocardial blood flow in coronary artery disease: Results in 25 patients and comparison with nitroglycerin
37. Use of sildenafil (Viagra) in patients with cardiovascular disease
38. Hemodynamic effects of Sildenafil in men with severe coronary artery disease
39. 'Traditional' Medical therapy in unstable angina: How important? How to use?
40. Diagnosing and managing unstable angina
41. Beta blockade during and after myocardial infarction: An overview of the randomized trials
42. Effect of verapamil on mortality and major events after acute myocardial infarction (The Danish Verapamil Infarction Trial II-DAVIT II)
43. The effect of diltiazem on mortality and reinfarction after myocardial infarction
44. Diltiazem and reinfarction in patients with non-Q-wave myocardial infarction: Results of a double-blind, randomized, multicenter trial
45. Unfractionated heparin and low-molecular-weight heparin in acute coronary syndrome without ST deviation: A meta-analysis
46. Will the use of low-molecular weight heparin (enoxaparin) in patients with acute coronary syndrome save costs in Canada?
47. Newer antiplatelet agents in acute coronary syndromes
48. Platelet glycoprotein IIb/IIIa receptor blockade in coronary artery disease
49. Platelet glycoprotein IIb/IIIa receptor blockers: An appropriate-use model for expediting care in acute coronary syndromes
50. Glycoprotein IIb/IIIa receptor antagonist: A review of the pivotal trials
51. Platelet glycoprotein IIb/IIA blockade with abciximab with low-dose heparin during percutaneous coronary revascularization
52. Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT II
53. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina
54. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction
55. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S)
56. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels
57. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels
58. Aggressive cholesterol lowering delays saphenous vein graft atherosclerosis in women, the elderly, and patients with associated risk factors: NHLBI Post-Coronary Artery Bypass Graft Clinical Trial